首页   按字顺浏览 期刊浏览 卷期浏览 Treatment of Resistant Hodgkin’s Disease with CCNU, Etoposide and Prednimustine (CEP)
Treatment of Resistant Hodgkin’s Disease with CCNU, Etoposide and Prednimustine (CEP)

 

作者: J. Szántó,   T. Fleischmann,   S. Eckhardt,  

 

期刊: Oncology  （Karger Available online 1991）
卷期: Volume 48, issue 6  

页码: 456-458

 

ISSN:0030-2414

 

年代: 1991

 

DOI:10.1159/000226980

 

出版商: S. Karger AG

 

关键词: Hodgkin’s disease;Chemotherapy;Third choice

 

数据来源: Karger

 

摘要:

Starting in January 1984, 63 patients with resistant Hodgkin’s disease received CEP as salvage –usually third-line – chemotherapy. Complete response (CR) was achieved in 3%, partial response (PR) in 51%. The median duration of remission (CR + PR) was greater than 15 months. Treatment was generally well tolerated. Our results confirm that CEP is an effective therapeutic regimen in resistant Hodgkin’s

 

点击下载:  PDF (892KB)



返 回